Renal Effects of Liraglutide Biosimilar Versus Reference Liraglutide in Indian Patients with Type 2 Diabetes: Post Hoc Findings from a Phase III Trial

Background: Chronic kidney disease is a common complication of type 2 diabetes mellitus (T2DM) and contributes substantially to cardiovascular morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including liraglutide, have demonstrated potential renal benefits in cardiovascular outcomes trials. Data on renal parameters with liraglutide biosimilars, particularly in Indian populations, remain limited.Methods: This post hoc exploratory analysis evaluated renal parameters from a randomized Phase III trial comparing a liraglutide biosimilar with reference liraglutide in Indian patients with T2DM. Changes in estimated glomerular filtration rate (eGFR), serum creatinine, and blood pressure were assessed from baseline to week 24. Within-group and between-group comparisons were performed using unadjusted statistical analyses.Results: A total of 241 participants with complete renal data were included (liraglutide biosimilar, n=123; reference liraglutide, n=118). Both treatment groups demonstrated statistically significant within-group improvements in eGFR and reductions in serum creatinine over 24 weeks. No statistically significant differences were observed between the biosimilar and reference liraglutide groups for eGFR or serum creatinine at week 24. Modest reductions in systolic and diastolic blood pressure were observed in both groups.Conclusion: In this post hoc analysis, liraglutide biosimilar and reference liraglutide were associated with comparable short-term changes in eGFR and serum creatinine in patients with T2DM. Given the exploratory design, short duration of follow-up, and reliance on surrogate renal markers, these findings should be interpreted cautiously. Prospective studies with longer follow-up and comprehensive renal endpoints are required to further characterize renal outcomes with liraglutide biosimilars

Authors

Institutions

Publication Details

Journal
Journal of Nephrology & Endocrinology Research
Published
2026-11-19
DOI
https://doi.org/10.47363/jone/2026(6)152
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Renal Effects of Liraglutide Biosimilar Versus Reference Liraglutide in Indian Patients with Type 2 Diabetes: Post Hoc Findings from a Phase III Trial

Sanjay Choudhari Choudhari
1 links
Journal of Nephrology & Endocrinology Research
Diabetes Treatment and Management
article

Renal Effects of Liraglutide Biosimilar Versus Reference Liraglutide in Indian Patients with Type 2 Diabetes: Post Hoc Findings from a Phase III Trial

Sanjay Choudhari Choudhari
article en

Abstract

Background: Chronic kidney disease is a common complication of type 2 diabetes mellitus (T2DM) and contributes substantially to cardiovascular morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including liraglutide, have demonstrated potential renal benefits in cardiovascular outcomes trials. Data on renal parameters with liraglutide biosimilars, particularly in Indian populations, remain limited.Methods: This post hoc exploratory analysis evaluated renal parameters from a randomized Phase III trial comparing a liraglutide biosimilar with reference liraglutide in Indian patients with T2DM. Changes in estimated glomerular filtration rate (eGFR), serum creatinine, and blood pressure were assessed from baseline to week 24. Within-group and between-group comparisons were performed using unadjusted statistical analyses.Results: A total of 241 participants with complete renal data were included (liraglutide biosimilar, n=123; reference liraglutide, n=118). Both treatment groups demonstrated statistically significant within-group improvements in eGFR and reductions in serum creatinine over 24 weeks. No statistically significant differences were observed between the biosimilar and reference liraglutide groups for eGFR or serum creatinine at week 24. Modest reductions in systolic and diastolic blood pressure were observed in both groups.Conclusion: In this post hoc analysis, liraglutide biosimilar and reference liraglutide were associated with comparable short-term changes in eGFR and serum creatinine in patients with T2DM. Given the exploratory design, short duration of follow-up, and reliance on surrogate renal markers, these findings should be interpreted cautiously. Prospective studies with longer follow-up and comprehensive renal endpoints are required to further characterize renal outcomes with liraglutide biosimilars

Journal of Nephrology & Endocrinology ResearchVol. 6(4)
Glenmark Pharmaceuticals (India) (IN)
Glenmark Pharmaceuticals, Department of Biotechnology, Ministry of Science and Technology, India, Biotechnology Industry Research Assistance Council
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon